genespire-logo def-01.jpg
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
25. September 2024 07:00 ET | Genespire
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings...
genespire-logo def-01.jpg
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
25. September 2024 01:00 ET | Genespire
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings...
genespire-logo def-01.jpg
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
12. September 2024 07:00 ET | Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
genespire-logo def-01.jpg
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
12. September 2024 01:00 ET | Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
genespire-logo def-01.jpg
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting
09. Mai 2024 12:00 ET | Genespire
PRESS RELEASE Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting Data provides preclinical validation for Genespire’s liver-directed lentiviral gene therapy in...
genespire-logo def-01.jpg
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer
07. Juli 2022 02:00 ET | Genespire
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the...
genespire-logo def-01.jpg
Genespire appoints Philippe Mauberna as Chief Financial Officer
13. Juli 2021 07:00 ET | Genespire
Genespire appoints Philippe Mauberna as Chief Financial Officer Former Nanobiotix Chief Financial Officer brings extensive experience in international life sciences finance, successful fundraisings...
genespire-logo def-01.jpg
Genespire Strengthens Management Team with Two Key Appointments
05. Mai 2021 07:00 ET | Genespire
Genespire Strengthens Management Team with Two Key Appointments Dr. Julianne Smith appointed Chief Development Officer Dr. Smaragda Angelidou appointed as Head of CMC Italy, Milan, 5 May 2021:...
genespire-logo def-01.jpg
Genespire appoints Jörn Aldag as Chairman of the Board of Directors
30. Juli 2020 07:00 ET | Genespire
Genespire appoints Jörn Aldag as Chairman of the Board of DirectorsSerial entrepreneur brings exceptional experience from a range of leadership roles Italy, Milan, 30 July 2020: Genespire, a gene...
genespire-logo def-01.jpg
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells
30. Juni 2020 07:00 ET | Genespire
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells Italy, Milan, 30 June...